Butts Ryan J, Boyle Gerard J, Deshpande Shriprasad R, Gambetta Katheryn, Knecht Kenneth R, Prada-Ruiz Carolina A, Richmond Marc E, West Shawn C, Lal Ashwin K
Pediatric Cardiology, Medical University of South Carolina, Charleston, SC, USA.
Department of Pediatric, 5323 Harry Hines Blvd, 9063, Dallas, TX, 75390-9063, USA.
Pediatr Cardiol. 2017 Aug;38(6):1175-1182. doi: 10.1007/s00246-017-1638-1. Epub 2017 May 23.
The objective of this study was to describe a contemporary cohort of pediatric patients hospitalized for clinically suspected myocarditis. A retrospective chart review was performed at seven tertiary pediatric hospitals. Electronic medical records were searched between 2008 and 2012 for patients ≤18 years admitted with an ICD-9 code consistent with myocarditis. Patients were excluded if the admitting or consulting cardiologist did not suspect myocarditis during the admission or an alternative diagnosis was determined. One hundred seventy-one patients were discharged or died with a primary diagnosis of myocarditis. Median age was 13.1 years (IQR 2.1, 15.9), with a bimodal distribution; 24% <2 years and 46% between 13 and 18 years. Patients with moderate or severe systolic dysfunction were younger, had higher BNPs at admission, but had lower troponin. Mortality, heart transplantation, and readmission did not differ between patients who received only IVIG, only steroids, IVIG and steroids, and no immunotherapy. Ninety-four patients (55%) were discharged on heart failure medications, 16 were transplanted, and seven died. The presence at the time of admission of gastrointestinal (GI) symptoms (p = 0.01) and lower echo shortening fraction (SF) (p < 0.01) was associated with death/transplant. Within one year 16% had a readmission, one underwent heart transplant, and 39% received heart failure therapy. Pediatric myocarditis has a bimodal age distribution. The use of IVIG and steroids is not associated with mortality/heart transplantation. The presence of GI symptoms and lower echo SF may identify patients at risk for death and/or transplantation during the admission.
本研究的目的是描述一组因临床疑似心肌炎住院的当代儿科患者。在七家三级儿科医院进行了回顾性病历审查。检索了2008年至2012年期间电子病历中年龄≤18岁、入院时ICD-9编码与心肌炎相符的患者。如果入院时接诊或会诊的心脏病专家不怀疑心肌炎或确定了其他诊断,则将患者排除。171例患者出院或死亡,主要诊断为心肌炎。中位年龄为13.1岁(四分位间距2.1, 15.9),呈双峰分布;24%小于2岁,46%在13至18岁之间。中度或重度收缩功能障碍的患者年龄较小,入院时BNP较高,但肌钙蛋白较低。仅接受静脉注射免疫球蛋白(IVIG)、仅接受类固醇、IVIG和类固醇联合治疗以及未接受免疫治疗的患者在死亡率、心脏移植和再入院方面没有差异。94例患者(55%)出院时服用心力衰竭药物,16例接受了心脏移植,7例死亡。入院时出现胃肠道(GI)症状(p = 0.01)和较低的超声心动图缩短分数(SF)(p < 0.01)与死亡/移植相关。一年内,16%的患者再次入院,1例接受心脏移植,39%的患者接受心力衰竭治疗。小儿心肌炎具有双峰年龄分布。IVIG和类固醇的使用与死亡率/心脏移植无关。GI症状的存在和较低的超声心动图SF可能有助于识别入院期间有死亡和/或移植风险的患者。